Tag: Erythropoiesis stimulating agent

PROCRIT is definitively not available over the counter, as confirmed by its manufacturer and the U.S. Food and Drug Administration (FDA). This is because PROCRIT (epoetin alfa) is a powerful, man-made protein that requires strict medical supervision due to its potential for serious side effects.

Despite being used to support patients undergoing cancer treatment, PROCRIT (epoetin alfa) is not a form of immunotherapy. Instead, it is an erythropoiesis-stimulating agent (ESA) that functions by stimulating the bone marrow to produce more red blood cells. This distinction is crucial for understanding its role in supportive care for anemia, a common side effect of chemotherapy and other medical conditions.

According to the National Kidney Foundation, anemia is a common complication of chronic kidney disease, affecting more than 30 million American adults. For patients seeking treatment for anemia, a frequent question arises: which is better, PROCRIT or Aranesp? While both drugs work similarly, their distinct dosing schedules and pharmacokinetic properties are key factors in determining the best choice for an individual's specific needs.

Mircera, an erythropoiesis-stimulating agent (ESA), was first approved by the FDA in 2007. The generic name for Mircera is methoxy polyethylene glycol-epoetin beta, a modified version of the naturally occurring hormone erythropoietin used to treat anemia associated with chronic kidney disease (CKD).

According to the National Kidney Foundation, anemia is a common complication of chronic kidney disease (CKD), affecting millions of people. For certain individuals, the prescription medication Procrit is used for anemia to help manage the condition by stimulating the body's natural red blood cell production.